Skip to content

Inspection Record

Charles River Laboratories — FDA 483 Findings

US FDAInspected 2025-02-07Published 2026-10-30 5 findingsDocumentation and recordsMaterial and supplier controlEquipment and facilityTraining and personnelAseptic processing and sterility assurance

Inspectors Scott T Ballard · Christian LynchThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Documentation and records

Master production and control records lack complete manufacturing and control instructions.

2Material and supplier control

Records fail to include an individual inventory record of each component and drug product container with sufficient information to allow determination of any associated batch or lot of drug product.

3Equipment and facility

Buildings used in the of a drug product are not maintained in a good state of repair.

4Training and personnel

Employees engaged in the manufacture and processing of a drug product lack the training required to perform their assigned functions.

5Aseptic processing and sterility assurance

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic process.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the US FDA document published on 2026-10-30. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Charles River Laboratories company profile — full historyAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.